• Luminate Medical is challenging the status quo in cancer care with the Lily device, which aims to prevent hair loss during chemotherapy.
  • Luminate Medical’s Lily device uses a non-invasive technique to protect hair follicles during treatment, attracting widespread media and investor interest.
  • Backed by Y Combinator and €5 million in funding, Luminate Medical is advancing toward commercializing Lily.

In the world of cancer treatment, one small device is poised to redefine the patient experience.

For millions, the visible scars of chemotherapy, particularly hair loss, are a constant reminder of their battle—a daily, unasked-for revelation of an intensely personal struggle.

Irish medtech startup Luminate Medical is challenging this painful norm, offering new hope through innovation.

Founded by visionary engineers Aaron Hannon, Barbara Oliveira, and Martin O'Halloran, Luminate Medical is pioneering a solution designed to protect cancer patients from the trauma of hair loss.

An Idea Born from Compassion

For the founders, this mission is more than business; it’s deeply personal. Co-founder Aaron Hannon, a Thiel Fellow and celebrated young innovator, was inspired to address the silent suffering experienced by countless chemotherapy patients.

Together with Oliveira and O'Halloran, he crafted an approach to hair loss prevention that is both groundbreaking and patient-focused.

Barbara Oliveira said: “Our mission is to revolutionise the user experience of healthcare. We do that by building medical devices with a patient-first approach and focusing on the needs that truly matter to patients.”

Their brainchild, the Lily device, was unveiled in 2021, sparking a wave of interest and optimism.

This non-invasive, wearable device temporarily limits blood flow to hair follicles during chemotherapy, shielding them from the harmful effects of cancer-fighting drugs—all without surgery, chemicals, or pills.

Through its innovative design, Lily holds the power to change how patients experience cancer treatment, placing Luminate Medical at the forefront of compassionate medtech.

“At Luminate, that’s what we do – build the products and tools that improve patients’ quality of life during and after treatment,” Oliveira said. “We have built a fantastic team of 16 who share the same ambition and commitment towards our mission.”

Lily: The Device Poised to Transform Cancer Care

The Lily device is more than just a technical marvel; it’s a promise. Hair loss often serves as an unwanted reminder of illness, stripping patients of their privacy and confidence.

Lily offers the possibility of preserving not only hair but also the dignity and sense of normalcy that so many patients desire.

With promising results from early trials, Luminate Medical’s solution may soon become a vital companion in cancer care.

“Five out of seven currently available antibody drug conjugates approved to treat cancer have side effects like hair loss. Our products are suitable for any patient, anywhere in the world, going through chemotherapy, with a combined $36bn global opportunity for Lily and Lilac,” said Oliveira.

Recognizing that innovation doesn’t happen in isolation, Luminate Medical is building relationships with healthcare professionals and patients, ensuring that Lily is as effective and accessible as possible.

Their online resources offer detailed information for both patients and physicians, demystifying the science behind the device and showcasing its potential.

A Bright Start Fueled by Global Recognition

Luminate’s transformative approach quickly attracted high-profile attention. The company joined Y Combinator’s 2021 batch, gaining support and visibility from one of the world’s top startup accelerators.

In the same year, Luminate Medical raised an impressive €5 million in funding, backed by Y Combinator and additional investors.

As it grows, Luminate Medical aims to make the Lily device widely available and to explore new solutions for other chemotherapy side effects.

Headquartered in Galway, Ireland, this ambitious startup is well on its way to transforming the field of cancer care.

“We envision a world where technology makes cancer care a personalised, at-home procedure that heals a person, not just a disease,” Oliveira continued.

Edited By Annette George